Atara Biotherapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: South San Francisco CA United States (2012)

Organization Overview

First Clinical Trial
2012
NCT00002663
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Atara Biotherapeutics | Santa Maria Biotherapeutics

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 1)

Communicable Diseases (Phase 2)

Cytomegalovirus Infections (Phase 2)

Endometrial Neoplasms (Phase 1)

Epstein-Barr Virus Infections (Phase 2)

Fallopian Tube Neoplasms (Phase 1)

Immunologic Deficiency Syndromes (Phase 2)

Infections (Phase 2)

Leiomyosarcoma (Phase 2)

Leukemia (Phase 1)

Lymphohistiocytosis, Hemophagocytic (Phase 2)

Lymphoma (Phase 2)

Lymphoproliferative Disorders (Phase 3)

Mesothelioma (Phase 1)

Multiple Sclerosis (Phase 1)

Multiple Sclerosis, Chronic Progressive (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Nasopharyngeal Carcinoma (Phase 2)

Nasopharyngeal Neoplasms (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 1)

Sclerosis (Phase 1)

Viremia (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial APIs: 13